| 0 (0%) | 09-17 23:16 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.18 |
1-year : | 21.78 |
| Resists | First : | 17.28 |
Second : | 18.64 |
| Pivot price | 16.22 |
|||
| Supports | First : | 15.06 |
Second : | 12.53 |
| MAs | MA(5) : | 15.61 |
MA(20) : | 16.35 |
| MA(100) : | 16.53  |
MA(250) : | 13.83 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 21.4 |
D(3) : | 21.8 |
| RSI | RSI(14): 33.3 |
|||
| 52-week | High : | 20.48 | Low : | 8.69 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IART ] has closed above bottom band by 1.1%. Bollinger Bands are 23.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.41 - 16.49 | 16.49 - 16.56 |
| Low: | 14.86 - 14.96 | 14.96 - 15.05 |
| Close: | 14.96 - 15.11 | 15.11 - 15.24 |
Thu, 17 Sep 2026
A Look at Integra Lifesciences Holdings Corp (IART) After 6.1% D - GuruFocus
Wed, 16 Sep 2026
Integra LifeSciences (IART) Stock Could Be Reasonable Despite A 77% Slump - simplywall.st
Tue, 15 Sep 2026
IART: Operational recovery and innovation set the stage for growth, margin expansion, and cash flow gains - TradingView
Tue, 15 Sep 2026
IART: Operational recovery and product relaunches set the stage for renewed growth and margin expansion - TradingView
Sat, 12 Sep 2026
Why Integra LifeSciences Holdings (IART) Is Back In The Spotlight - simplywall.st
Thu, 10 Sep 2026
3 Reasons IART is Risky and 1 Stock to Buy Instead - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 78 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 14.3 (%) |
| Held by Institutions | 98.3 (%) |
| Shares Short | 6,740 (K) |
| Shares Short P.Month | 6,210 (K) |
| EPS | -0.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.4 |
| Profit Margin | -0.5 % |
| Operating Margin | 9.6 % |
| Return on Assets (ttm) | 2.8 % |
| Return on Equity (ttm) | -0.7 % |
| Qtrly Rev. Growth | 0.8 % |
| Gross Profit (p.s.) | 12.04 |
| Sales Per Share | 21.21 |
| EBITDA (p.s.) | 4.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 85 (M) |
| Levered Free Cash Flow | 94 (M) |
| PE Ratio | -167.78 |
| PEG Ratio | 0.6 |
| Price to Book value | 1.12 |
| Price to Sales | 0.71 |
| Price to Cash Flow | 13.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|